Sean Fletcher

Urologic Oncology Fellow @MSKCancerCenter @UrologyMSK | Alum @Brady_Urology @HarvardMed @Yale

[Nick Pickersgill, MD @NickPickersgill]

New in @BJUIjournal: PSMA-PET/CT in pN1 prostate cancer

• Poor sensitivity for LNI in high-risk pts; negative PSMA-PET does not justify omitting PLND
• PSMA+ nodal disease = nearly guaranteed BCR & radiographic progression (1-yr BCR ~84%)
• Do these patients need adjuvant treatment intensification? Prospective trials needed

@UrologyMSK @SeanFletcherMD @VickersBiostats

https://t.co/v6B7SfA3kN

[Andrew Vickers @VickersBiostats]

"Due to low sensitivity, PSMA-PET/CT without evidence of nodal disease does not obviate the need for PLND" BUT "PSMA-avid nodal disease portends ... nearly inevitable ... recurrence and radiographic progression, supporting treatment intensification." https://t.co/0p3blERPj2

[Matt Cooperberg @dr_coops]

More insights from @MSKCancerCenter re: N+ #prostatecancer. Confirming PSMA PET ≠ PLND, PLND alone is not commonly curative, tx needs to be multimodal. #GU26 @SeanFletcherMD

[ari hakimi @arihakimi]

Great night out with our all star fellows at #SUO2025 lo

[UrologyMSK @UrologyMSK]

Interested in learning about the oldest and largest urologic oncology fellowship in the world? Join us in our virtual open house wed Nov 12th at 7 pm EST Hear from faculty and current fellows!!

https://t.co/pZDjdvWCEK

Sign up: https://t.co/ouDww8278U

[Sean Fletcher @SeanFletcherMD]

Great opportunity to learn at #ECIW2025

[Amer. Urol. Assn. @AmerUrological]

One-on-one mentoring between mentors and early career mentees at this weekends #ECIW2025.

#Urology #AUA

[Nick Pickersgill, MD @NickPickersgill]

New in @JAMAOnc: Our study of >11,000 PLCO participants shows that ~25% of elevated PSA values fall below threshold within a year, but persistent elevations rarely do (<10%), and should proceed directly to further eval.

@SigridCarlsson @MariaPereMD @UrologyMSK @VickersBiostats

[Sean Fletcher @SeanFletcherMD]

Check out our Clinical Consultation Guide on Neoadjuvant Chemotherapy for Upper Tract Urothelial Cancer, published in @EurUrolFocus

@nirmishsingla @JCensits

https://t.co/iJWH2qKQD4

[Advanced Prostate Cancer Consensus Conference @APCCC_Lugano]

Family History of Prostate, Breast, Ovarian, and/or Pancreatic Cancer and Associations with Grade Reclassification in a Large Prostate Cancer Active Surveillance Cohort

https://t.co/OwEyrkzOqL

In a prospective cohort of 1,421 prostate cancer patients on active surveillance, family history of #ProstateCancer (FH-Pr) was associated with a higher risk of grade reclassification, including progression to Gleason grade ≥3, whereas family history of breast, ovarian, or pancreatic cancer (FH-BOPa) was not. Among 349 patients who underwent radical prostatectomy, no family history was linked to adverse pathological features.

These findings suggest that patients with a FH of prostate cancer can remain on active surveillance but may benefit from closer monitoring.

@ClaireDlc
@SeanFletcherMD
@KatarzynaMacura
@LotanLab
William B. Isaacs @brady_Urology
Christian P. Pavlovich

@OncoAlert 🚨
@Silke_Gillessen
@AOmlin
@nataliagandur
@bavilima

[Sean Fletcher @SeanFletcherMD]

Major congrats to @LoganGalanskyMD & huge win for @BostonChildrens !

[Mohamad Allaf @allaf_mo]

Big Congratulations to @LoganGalanskyMD for matching @BostonChildrens Pediatric Urology Fellowship! A former AUA Holtgrewe Legislative Fellow, meticulous surgeon, and future leader. We are all so proud of Logan!!

[Sean Fletcher @SeanFletcherMD]

Out in @BJUIjournal: Retro cohort study on detection of GG2+ PCa on systematic biopsy outside of MRI ROI (n=481 biopsies @brady_urology)
- 6.4% with GG2+ outside of ROI
- 1.5% with GG2+ contralateral to ROI
- No association w baseline factors (e.g. PSA-D)

https://t.co/7HLNxm86HF

[Sean Fletcher @SeanFletcherMD]

Honor and a pleasure to end residency with the Peds team 🫡 @DrG_PedsUro @heathernoellemc @dr_chad11 @CharlotteWuMD @VictoriaMaxon @madip_pac

[Chad Crigger, MD, MPH @dr_chad11]

Final Chief send off for this year, this time for @HopkinsMedicine @brady_urology’s @SeanFletcherMD. Cool, calm and collected, I’m convinced nothing can phase him. @UrologyMSK and @MSKCancerCenter are getting a thoughtful, talented surgeon and future leader in Urology.

[Sean Fletcher @SeanFletcherMD]

Feels a bit surreal to be done — so grateful to have trained @brady_urology with world class faculty, staff & co-residents!

[Charlotte Wu @CharlotteWuMD]

Huge congrats to this outstanding chief class @SeanFletcherMD, @urogabe, and Katie Mahon on completing their residency today! We are so proud of you! @brady_urology @allaf_mo

[Sean Fletcher @SeanFletcherMD]

Major congrats to @ztonysu & @theNCI !!

[Mohamad Allaf @allaf_mo]

Congratulations to Dr. Tony Su matching @theNCI for @UroOnc SUO fellowship! Joining former @brady_urology alumni @markballmd & Peter Pinto. Tony is an amazing surgeon-scientist and glad to have him "down the street!"

[Mohamad Allaf @allaf_mo]

Great pic of our recent VP @SBoorjian and @brady_urology learners! Again thank u for a great visit. @urogabe @SeanFletcherMD @LoganGalanskyMD @VictoriaMaxon @MarkAlshakMD

[Sean Fletcher @SeanFletcherMD]

Thanks to @samhaywoodmd for highlighting our work in “Three Papers that Influenced my Practice” during #SUO session #AUA2025 @y_bhanji @SUO_YUO @UroOnc

[Yasin Bhanji @y_bhanji]

Excited to share our team’s work @brady_urology describing the evolution of AS for PCa in the modern era! Is Confirmatory Biopsy Still Necessary for Active... : Journal of Urology https://t.co/QiEIGKpTnz

[Charlotte Wu @CharlotteWuMD]

Come on over to booth #361 to learn about our residency program, try out our VR surgery simulator, and meet with our team! @brady_urology @SLICE_JHU @aghazimd #AUA2025

[Charlotte Wu @CharlotteWuMD]

Last night's Brady dinner- an evening of good food and conversation with Dr. Allaf, Kate, and our wonderful residents and fellows!

[Sean Fletcher @SeanFletcherMD]

Congrats and welcome!!

[The Johns Hopkins Brady Urological Institute @brady_urology]

We're proud to announce the @HopkinsMedicine Brady Urological Institute Residency Class of 2030!

Congratulations and welcome to the team!! #urologymatch2025 #MatchDay

[MPallauf @PallaufM]

Proud to share our latest DISSRM publication, which explores the relationship between tumor size and growth rates in small renal masses among patients undergoing active surveillance https://t.co/MCntUEALfI